SynthesisPharmaceutical research2026
A Comprehensive Review of the Revolutionary Potential of Blockchain in Safe, Secure, and Sustainable Pharmaceutical Operations.
Synthesis in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPharmaceutical research and industrial operations generate vast volumes of sensitive data across drug discovery, formulation development, manufacturing, and distribution, necessitating secure, transparent, and reliable digital infrastructures. The global counterfeit drug market exceeds $200 billion annually, posing a significant threat to patient safety and public health. Blockchain Technology (BT) has demonstrated the potential to reduce counterfeit medicine circulation by approximately 40%, offering a transformative framework for pharmaceutical data governance.
methodsA systematic literature review was performed using ScienceDirect, PubMed, IEEE Xplore, and SpringerLink databases to analyze peer-reviewed studies published between January 2017 and December 2024. Structured keyword strategies and predefined inclusion and exclusion criteria were employed to evaluate blockchain-driven pharmaceutical operations and their integration with Artificial Intelligence (AI) and the Internet of Things (IoT).
resultsThe findings reveal that BT substantially improves data integrity, immutability, traceability, transparency, and security across pharmaceutical workflows. Integration with AI and IoT further enables real-time monitoring and predictive analytics, leading to 30-55% improvements in operational efficiency, 25-50% reductions in logistics and compliance-related costs, and significant enhancements in clinical trial data accuracy, pharmacovigilance reporting efficiency, intellectual property protection, and genomic data governance and counterfeit drug prevention.
conclusionBlockchain-driven pharmaceutical ecosystems represent a paradigm shift in drug development, manufacturing, and distribution. Despite substantial benefits, challenges related to scalability, interoperability, data governance, and regulatory harmonization remain. Future research should prioritize the development of standardized frameworks, scalable architectures, and regulatory policies to accelerate industrial adoption and clinical translation.
Indexed as
Identifiers
41888483What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.